AUTHORS
David Levitz, MD, Ridhi Gupta, MD2, Amit Verma, MD3, Eric Feldman4
AFFILIATIONS
1 Montefiore Medical Center, Bronx, New York, United States
2 Montefiore Medical Center, Bronx, New York, United States
3 Montefiore Medical Center, Bronx, New York, United States
4 Montefiore Medical Center, Bronx, New York, United States
ABSTRACT
Background:
Multiple Myeloma (MM) is a malignant neoplasm of plasma cells accounting for approximately 36,000 new cases annually and 12,500 deaths. Patients who have relapsed after proteosome inhibitors, immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies are considered “triple-class refractory” and historically have demonstrated poor response rates and short overall survival. More recently, BCMA and GPRC5D targeted therapies have significantly improved response rates with robust durability in the relapsed population. Concurrent BCMA- and GPRC5D-targeting therapies have already been studied in the RedirecTT-1 and RedirectTT-2 trials, as well as JNJ-5322 trispecific under development which targets BCMA, GPRC5D and T-cell CD3. However, these previous studies all use Bispecific T-Cell Engagers (two targets, one mechanism of action).
We hypothesize the combination of Belantamab mafodotin (Bela) with Talquetamab (Tal) will provide dual-antigen targeting with complementary cytotoxic (T-Cell independent) and T-Cell-mediated mechanisms that can deepen responses, reduce antigen escape, and delay progression.
Objective:
The primary objective of this study is to determine the safety, tolerability, and the optimal biological dosing of the combination of Tal and Bela followed by Bela and Pomalidomide (Pom) maintenance in patients with relapsed/refractory multiple myeloma. Our secondary endpoints are the ORR, duration of response, rate of MRD negativity and rate of sustained MRD negativity (defined as sustained > 1 year), time to progression, time to next treatment, PFS and OS.
Design:
This is a phase 1, two part open-label dose escalation study evaluating the safety and clinical efficacy of Tal in combination with Bela for a time-limited interval of > 6 cycles followed by Bela/Pom maintenance. Participants who demonstrate sustained MRD negativity on two separate bone marrow biopsies > 1 year apart may hold all study therapy for a treatment free interval. In Part 1, we are utilizing a BOIN design escalating both Tal and Bela in parallel starting at Tal 0.4mg/kg q2weeks and Bela 1.4mg/kg q8weeks, escalating to a maximum dose of Tal 0.8mg/kg q2weeks and Bela 1.9mg/kg q8weeks. In part 2, up to 12 patients will be randomized across 2 dose levels based on patient safety data to determine the optimal biological dose.
Eligible patients must have relapsed/refractory Multiple Myeloma who have been exposed to at least 1 prior line of MM therapy and been exposed to an IMiD, PI, and anti-CD38 agent, are > 18 years of age, have measurable disease as defined by IMWG criteria (or have active bone findings on PET/CT or a measurable plasmacytoma in dose escalation phase), and meet standard laboratory criteria.
Disease response by IMWG criteria will be assessed at the beginning of each cycle. MRD analysis will be performed via Clonoseq with sensitivity of 10^-6. Treatment will consist of Tal step-up dosing to TD1 as per standard of care, followed by concurrent Tal/Bela dosing on C1D1. Each cycle will be 28 days long with Tal dosed q2weeks and Bela on D1 of every other cycle. Patients who achieve > VGPR after 6 cycles can transition to Bela/Pom/dex maintenance.
Conclusion:
This study will evaluate the optimal dosing of Talquetamab and Belantamab mafodotin combination therapy with regards to both safety as well as efficacy based on depth of response and durability of remission. We hypothesize that the dual mechanisms of action of the combined therapy will improve upon the historical response rates of either drug separately without excess toxicity.
DISCLOSURES
David Levitz, MD: No relevant conflicts of interest to declare.